F. Barlesi, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), The Lancet, vol.387, issue.10026, pp.1415-1441, 2016.
DOI : 10.1016/S0140-6736(16)00004-0

M. Soda, Identification of the transforming EML4???ALK fusion gene in non-small-cell lung cancer, Nature, vol.276, issue.7153, pp.561-567, 2007.
DOI : 10.1016/S0002-9440(10)62574-6

A. T. Shaw, -Positive Lung Cancer, New England Journal of Medicine, vol.368, issue.25, pp.2385-94, 2013.
DOI : 10.1056/NEJMoa1214886

URL : https://hal.archives-ouvertes.fr/hal-00953826

B. J. Solomon, -Positive Lung Cancer, New England Journal of Medicine, vol.371, issue.23, pp.2167-77, 2014.
DOI : 10.1056/NEJMoa1408440

URL : https://hal.archives-ouvertes.fr/halshs-00919639

D. Castro and G. J. , First-line Ceritinib Versus Chemotherapy in Patients With ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4). in, 2016.

G. Scagliotti, Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study, Annals of Oncology, vol.27, issue.suppl_6, 2016.
DOI : 10.1093/annonc/mdw435.41

S. M. Gadgeel, Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study, The Lancet Oncology, vol.15, issue.10, pp.1119-1147, 2014.
DOI : 10.1016/S1470-2045(14)70362-6

H. Y. Zou, PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models, Cancer Cell, vol.28, issue.1, pp.70-81, 2015.
DOI : 10.1016/j.ccell.2015.05.010

S. N. Gettinger, Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial, The Lancet Oncology, vol.17, issue.12, pp.1683-1696, 2016.
DOI : 10.1016/S1470-2045(16)30392-8

S. H. Ou, Rearranged Non???Small-Cell Lung Cancer: A Phase II Global Study, Journal of Clinical Oncology, vol.34, issue.7, pp.661-669, 2016.
DOI : 10.1200/JCO.2015.63.9443

A. T. Shaw, Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial, The Lancet Oncology, vol.17, issue.2, pp.234-276, 2016.
DOI : 10.1016/S1470-2045(15)00488-X

L. Cameron and B. Solomon, New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer, Current Treatment Options in Oncology, vol.7, issue.12, p.49, 2015.
DOI : 10.1097/JTO.0b013e3182745948

S. Khozin, FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.21, issue.11, pp.2436-2439, 2015.
DOI : 10.1158/1078-0432.CCR-14-3157

M. Santarpia, G. Altavilla, and R. Rosell, Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer, Expert Review of Respiratory Medicine, vol.23, issue.152, pp.255-268, 2015.
DOI : 10.1158/1078-0432.CCR-12-3381

M. Duruisseaux, Overall survival with crizotinib and next-generation ALK inhibitors in ALKpositive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study, Oncotarget

N. I. Lindeman, Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology, J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer, vol.8, pp.823-859, 2013.

F. Cabillic, Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non???Small-Cell Lung Cancers Reveal Major Discordances, Journal of Thoracic Oncology, vol.9, issue.3, pp.295-306, 2014.
DOI : 10.1097/JTO.0000000000000072

URL : https://hal.archives-ouvertes.fr/hal-01064002

M. I. Ilie, ???borderline???-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies, Annals of Oncology, vol.26, issue.1, pp.238-282, 2015.
DOI : 10.1093/annonc/mdu484

S. Lantuejoul, rearrangement diagnostic in 547 lung adenocarcinomas, European Respiratory Journal, vol.46, issue.1, pp.207-218, 2015.
DOI : 10.1183/09031936.00119914

M. Von-laffert, ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making, Lung Cancer, vol.90, issue.3, pp.465-71, 2015.
DOI : 10.1016/j.lungcan.2015.09.022

A. Uguen, ALK ambiguous-positive non-small cell lung cancers are tumors challenged by diagnostic and therapeutic issues, Oncology Reports, vol.36, issue.3, pp.1427-1461, 2016.
DOI : 10.3892/or.2016.4962

A. Marchetti, ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm, Journal of Thoracic Oncology, vol.11, issue.4, pp.487-95, 2016.
DOI : 10.1016/j.jtho.2015.12.111

Y. J. Cha, H. R. Kim, and H. S. Shim, Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants, Journal of Translational Medicine, vol.24, issue.1, p.296, 2016.
DOI : 10.1093/annonc/mds242

Y. Y. Lei, Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC, Clinical Lung Cancer, vol.17, issue.3, pp.223-254, 2016.
DOI : 10.1016/j.cllc.2015.09.002

C. G. Woo, -rearranged non???small cell lung cancer, Annals of Oncology, vol.693, 2016.
DOI : 10.1093/annonc/mdw693

URL : https://hal.archives-ouvertes.fr/tel-01488898

T. Yoshida, -Positive Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.34, issue.28, pp.3383-3392, 2016.
DOI : 10.1200/JCO.2015.65.8732

URL : https://hal.archives-ouvertes.fr/hal-01486034

J. M. Heuckmann, Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants, Clinical Cancer Research, vol.18, issue.17, pp.4682-90, 2012.
DOI : 10.1158/1078-0432.CCR-11-3260

Q. Wang, J. Xia, P. Jia, W. Pao, and Z. Zhao, Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives, Briefings in Bioinformatics, vol.14, issue.4, pp.506-519, 2013.
DOI : 10.1093/bib/bbs044

Z. Zheng, Anchored multiplex PCR for targeted next-generation sequencing, Nature Medicine, vol.40, issue.12, pp.1479-84, 2014.
DOI : 10.1093/nar/gks596

A. Drilon, Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches, Clinical Cancer Research, vol.21, issue.16, pp.3631-3640, 2015.
DOI : 10.1158/1078-0432.CCR-14-2683

M. Pekar-zlotin, Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer, The Oncologist, vol.20, issue.3, pp.316-322, 2015.
DOI : 10.1634/theoncologist.2014-0389

C. Heydt, A. Kostenko, S. Merkelbach-bruse, J. Wolf, and R. Büttner, ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology, Annals of Oncology, vol.27, issue.suppl_3, pp.25-34, 2016.
DOI : 10.1093/annonc/mdw303

J. S. Jang, Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH??and IHC in Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.11, issue.11, pp.1891-1900, 2016.
DOI : 10.1016/j.jtho.2016.06.001

K. König, Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients, Journal of Thoracic Oncology, vol.10, issue.7, pp.1049-1057, 2015.
DOI : 10.1097/JTO.0000000000000570

W. D. Travis, International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.6, issue.2, pp.244-85, 2011.
DOI : 10.1097/JTO.0b013e318206a221

URL : https://hal.archives-ouvertes.fr/inserm-00561753

W. D. Travis, The 2015 World Health Organization Classification of Lung Tumors, Journal of Thoracic Oncology, vol.10, issue.9, pp.1243-1260, 2015.
DOI : 10.1097/JTO.0000000000000630

S. Dufort, M. J. Richard, S. Lantuejoul, and F. De-fraipont, Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC, Journal of Experimental & Clinical Cancer Research, vol.30, issue.1, 2011.
DOI : 10.1158/1078-0432.CCR-05-2324

URL : https://hal.archives-ouvertes.fr/inserm-00602408

A. Mcleer-florin, Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study, Journal of Thoracic Oncology, vol.7, issue.2, pp.348-54, 2012.
DOI : 10.1097/JTO.0b013e3182381535

N. Pfarr, High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer, Genes, Chromosomes and Cancer, vol.20, issue.1, pp.30-44, 2016.
DOI : 10.1038/nm.3729

C. T. Hiley, Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease, The Lancet, vol.388, issue.10048, pp.1002-1013, 2016.
DOI : 10.1016/S0140-6736(16)31340-X

S. Goodwin, J. D. Mcpherson, and W. Mccombie, Coming of age: ten years of next-generation sequencing technologies, Nature Reviews Genetics, vol.4, issue.6, pp.333-351, 2016.
DOI : 10.1111/j.1755-0998.2011.03024.x

S. M. Ali, -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization, The Oncologist, vol.21, issue.6, pp.762-70, 2016.
DOI : 10.1634/theoncologist.2015-0497

URL : https://hal.archives-ouvertes.fr/hal-01483447

A. G. Iyevleva, Novel ALK fusion partners in lung cancer, Cancer Letters, vol.362, issue.1, pp.116-121, 2015.
DOI : 10.1016/j.canlet.2015.03.028

B. Hallberg and R. H. Palmer, The role of the ALK receptor in cancer biology, Annals of Oncology, vol.27, issue.suppl_3, pp.4-15, 2016.
DOI : 10.1093/annonc/mdw301

Y. Togashi, An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer: Figure 1., Annals of Oncology, vol.26, issue.8, pp.1800-1801, 2015.
DOI : 10.1093/annonc/mdv240

J. M. Heuckmann, P. Pauwels, and E. Thunnissen, Comprehensive Hybrid Capture???Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative by FISH, Journal of Thoracic Oncology, vol.12, issue.3, pp.22-24, 2017.
DOI : 10.1016/j.jtho.2016.11.2229

A. T. Shaw, -Rearranged Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.371, issue.21, pp.1963-1971, 2014.
DOI : 10.1056/NEJMoa1406766

URL : https://hal.archives-ouvertes.fr/hal-00953826

Z. Song, X. Yu, and Y. Zhang, Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma, Lung Cancer, vol.101, pp.16-21, 2016.
DOI : 10.1016/j.lungcan.2016.09.002

C. G. Woo, Differential protein stability and clinical responses of EML4-ALKfusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, 2016.

S. Peters, -Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.377, issue.9, pp.10-1056, 2017.
DOI : 10.1056/NEJMoa1704795

URL : https://hal.archives-ouvertes.fr/hal-01485931

A. Shaw, D. Kim, K. Nakagawa, T. Seto, L. Crinó et al., -Positive Lung Cancer, New England Journal of Medicine, vol.368, issue.25, pp.2385-2394, 2013.
DOI : 10.1056/NEJMoa1214886

URL : https://hal.archives-ouvertes.fr/hal-00953826

B. Solomon, T. Mok, D. Kim, Y. Wu, K. Nakagawa et al., -Positive Lung Cancer, PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer, pp.2167-2177, 2014.
DOI : 10.1056/NEJMoa1408440

URL : https://hal.archives-ouvertes.fr/halshs-00919639

L. Crinò, M. Ahn, D. Marinis, F. Groen, H. Wakelee et al., Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From

D. Kim, R. Mehra, D. Tan, E. Felip, L. Chow et al., Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial, The Lancet Oncology, vol.17, issue.4, pp.452-463, 2016.
DOI : 10.1016/S1470-2045(15)00614-2

A. Shaw, T. Kim, L. Crinò, C. Gridelli, K. Kiura et al., Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, vol.18, issue.7, 2017.
DOI : 10.1016/S1470-2045(17)30339-X

C. Woo, S. Seo, S. Kim, S. Jang, K. Park et al., Differential protein stability and clinical responses of EML4-ALKfusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer, Ann. Oncol, 2016.

T. Yoshida, Y. Oya, K. Tanaka, J. Shimizu, Y. Horio et al., -Positive Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.34, issue.28, pp.3383-3389, 2016.
DOI : 10.1200/JCO.2015.65.8732

URL : https://hal.archives-ouvertes.fr/hal-01486034

J. Gainor, D. Tan, D. Pas, T. Solomon, B. Ahmad et al., Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib, Clinical Cancer Research, vol.21, issue.12, pp.2745-2752, 2015.
DOI : 10.1158/1078-0432.CCR-14-3009

Y. Togashi, M. Soda, S. Sakata, E. Sugawara, S. Hatano et al., KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only, PLoS ONE, vol.12, issue.2, p.31323, 2012.
DOI : 10.1371/journal.pone.0031323.s002

S. Peters, D. Camidge, A. Shaw, S. Gadgeel, J. Ahn et al., -Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.377, issue.9, 2017.
DOI : 10.1056/NEJMoa1704795

URL : https://hal.archives-ouvertes.fr/hal-01485931

I. Yeh, Clinical, Histopathologic, and Genomic Features of Spitz Tumors With ALK Fusions, The American Journal of Surgical Pathology, vol.39, issue.5, pp.581-591, 2015.
DOI : 10.1097/PAS.0000000000000387

J. J. Lin, G. J. Riely, and A. Shaw, Targeting ALK: Precision Medicine Takes on Drug Resistance, Cancer Discovery, vol.7, issue.2, pp.137-155, 2017.
DOI : 10.1158/2159-8290.CD-16-1123

P. Pierre, J. Scheel, J. E. Rickard, and T. E. Kreis, CLIP-170 links endocytic vesicles to microtubules, Cell, vol.70, issue.6, pp.887-900, 1992.
DOI : 10.1016/0092-8674(92)90240-D

X. Sun, Regulation of tumor angiogenesis by the microtubule-binding protein CLIP-170, Protein & Cell, vol.17, issue.4, pp.266-276, 2013.
DOI : 10.1038/nm.2537

W. D. Travis, The 2015 World Health Organization Classification of Lung Tumors, Journal of Thoracic Oncology, vol.10, issue.9, pp.1243-1260, 2015.
DOI : 10.1097/JTO.0000000000000630

N. Rekhtman, Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma, Modern Pathology, vol.6, issue.4, pp.511-522, 2013.
DOI : 10.1200/JCO.2007.15.0375

G. Rossi, Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology, Virchows Archiv, vol.29, issue.1, pp.61-68, 2014.
DOI : 10.1007/s10555-010-9205-8

J. F. Gainor, ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.19, issue.15
DOI : 10.1158/1078-0432.CCR-13-0318

A. Karlsson, Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer, Oncotarget, vol.6, issue.26, pp.22028-22037, 2015.
DOI : 10.18632/oncotarget.4314

G. Lou, X. Yu, and Z. Song, Molecular Profiling and Survival of Completely Resected Primary Pulmonary Neuroendocrine Carcinoma, Clinical Lung Cancer, vol.18, issue.3, pp.197-201, 2017.
DOI : 10.1016/j.cllc.2016.11.014

N. Omachi, A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4???ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib, Journal of Thoracic Oncology, vol.9, issue.6
DOI : 10.1097/JTO.0000000000000103

Y. Kobayashi, Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies, Journal of Thoracic Oncology, vol.8, issue.8, pp.75-78, 2013.
DOI : 10.1097/JTO.0b013e318293d96f

C. Caumont, Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma, Lung Cancer, vol.92, pp.15-18, 2016.
DOI : 10.1016/j.lungcan.2015.12.001

L. V. Sequist, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors, Science Translational Medicine, vol.105, issue.34, pp.75-101, 2011.
DOI : 10.1073/pnas.0803217105

J. M. Heuckmann, Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants, Clinical Cancer Research, vol.18, issue.17, pp.4682-4690, 2012.
DOI : 10.1158/1078-0432.CCR-11-3260

T. Yoshida, -Positive Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.34, issue.28, pp.3383-3389, 2016.
DOI : 10.1200/JCO.2015.65.8732

URL : https://hal.archives-ouvertes.fr/hal-01486034

C. G. Woo, -rearranged non???small cell lung cancer, Annals of Oncology, vol.693, 2016.
DOI : 10.1093/annonc/mdw693

URL : https://hal.archives-ouvertes.fr/tel-01488898

F. Barlesi, J. Mazieres, J. Merlio, D. Debieuvre, J. Mosser et al., Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), The Lancet, vol.387, issue.10026, 2016.
DOI : 10.1016/S0140-6736(16)00004-0

J. Guan, G. Umapathy, Y. Yamazaki, G. Wolfstetter, P. Mendoza et al., FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. eLife [Internet] Available from, 2015.

A. Reshetnyak, P. Murray, X. Shi, E. Mo, J. Mohanty et al., Augmentor ?? and ?? (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand???receptor interactions, Proceedings of the National Academy of Sciences, vol.9, issue.6, pp.15862-15869, 2015.
DOI : 10.7554/eLife.09811

M. Soda, Y. Choi, M. Enomoto, S. Takada, Y. Yamashita et al., Identification of the transforming EML4???ALK fusion gene in non-small-cell lung cancer, Nature, vol.276, issue.7153, pp.561-567, 2007.
DOI : 10.1016/S0002-9440(10)62574-6

E. Kwak, Y. Bang, D. Camidge, A. Shaw, B. Solomon et al., Anaplastic Lymphoma Kinase Inhibition in Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.363, issue.18, pp.1693-703, 2010.
DOI : 10.1056/NEJMoa1006448

F. Tabbó, ALK signaling and target therapy in anaplastic large cell lymphoma Available from, Front Oncol, vol.2, 2012.

T. Sasaki and P. Janne, New Strategies for Treatment of ALK-Rearranged Non-Small Cell Lung Cancers. Clin Cancer Res, pp.7213-7221, 2011.

S. Rodig, M. Mino-kenudson, S. Dacic, B. Yeap, A. Shaw et al., Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population, Clinical Cancer Research, vol.15, issue.16, pp.5216-5239, 2009.
DOI : 10.1158/1078-0432.CCR-09-0802

B. Solomon, T. Mok, D. Kim, Y. Wu, K. Nakagawa et al., -Positive Lung Cancer, New England Journal of Medicine, vol.371, issue.23, pp.2167-77, 2014.
DOI : 10.1056/NEJMoa1408440

URL : https://hal.archives-ouvertes.fr/halshs-00919639

A. Shaw, D. Kim, K. Nakagawa, T. Seto, L. Crinó et al., -Positive Lung Cancer, New England Journal of Medicine, vol.368, issue.25, pp.2385-94, 2013.
DOI : 10.1056/NEJMoa1214886

URL : https://hal.archives-ouvertes.fr/hal-00953826

J. Gainor, L. Dardaei, S. Yoda, L. Friboulet, I. Leshchiner et al., Molecular Mechanisms of Resistance to First-and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov, pp.1118-1151, 2016.

A. Shaw, T. Kim, L. Crinò, C. Gridelli, K. Kiura et al., Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, vol.18, issue.7, 2017.
DOI : 10.1016/S1470-2045(17)30339-X

S. Peters, D. Camidge, A. Shaw, S. Gadgeel, J. Ahn et al., -Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.377, issue.9, 2017.
DOI : 10.1056/NEJMoa1704795

URL : https://hal.archives-ouvertes.fr/hal-01485931

I. Dagogo-jack and A. Shaw, Crizotinib resistance: implications for therapeutic strategies, Annals of Oncology, vol.27, issue.suppl_3, pp.42-50, 2016.
DOI : 10.1093/annonc/mdw305

S. Ou, C. Bartlett, M. Mino-kenudson, J. Cui, and A. Iafrate, -Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology, The Oncologist, vol.17, issue.11, pp.1351-75, 2012.
DOI : 10.1634/theoncologist.2012-0311

URL : https://hal.archives-ouvertes.fr/halshs-01556558

L. Horn and W. Pao, : Honing In on a New Target in Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.27, issue.26, pp.4232-4237, 2009.
DOI : 10.1200/JCO.2009.23.6661

T. Sasaki, S. Rodig, L. Chirieac, and P. Jänne, The biology and treatment of EML4-ALK non-small cell lung cancer, European Journal of Cancer, vol.46, issue.10, pp.1773-80, 1990.
DOI : 10.1016/j.ejca.2010.04.002

J. Lin, G. Riely, and A. Shaw, Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov, Feb, vol.7, issue.2, pp.137-55, 2017.
DOI : 10.1158/2159-8290.cd-16-1123

S. Lantuejoul, I. Rouquette, H. Blons, L. Stang, N. Ilie et al., French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas, Eur Respir J, p.2015

F. Cabillic, A. Gros, F. Dugay, H. Begueret, L. Mesturoux et al., Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non???Small-Cell Lung Cancers Reveal Major Discordances, Journal of Thoracic Oncology, vol.9, issue.3, pp.295-306
DOI : 10.1097/JTO.0000000000000072

URL : https://hal.archives-ouvertes.fr/hal-01064002

A. Marchetti, D. Lorito, A. Pace, M. Iezzi, M. Felicioni et al., ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm, Journal of Thoracic Oncology, vol.11, issue.4, 2016.
DOI : 10.1016/j.jtho.2015.12.111

J. Wang, Y. Cai, Y. Dong, J. Nong, L. Zhou et al., Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements Detected by, PLoS ONE Jul, vol.39, issue.7, p.101551, 2014.

A. Marchetti, M. Pace, D. Lorito, A. Canarecci, S. Felicioni et al., Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays, Lung Cancer, vol.99, pp.11-17, 2016.
DOI : 10.1016/j.lungcan.2016.06.005

E. Lander, L. Linton, B. Birren, C. Nusbaum, M. Zody et al., Initial sequencing and analysis of the human genome, Nature, vol.6, issue.6822, pp.860-921, 2001.
DOI : 10.1089/cmb.1999.6.91

A. Hamblin, S. Wordsworth, J. Fermont, S. Page, K. Kaur et al., Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service, PLOS Medicine, vol.3, issue.6, p.1002230, 2017.
DOI : 10.1371/journal.pmed.1002230.s018

C. Kandoth, M. Mclellan, F. Vandin, K. Ye, B. Niu et al., Mutational landscape and significance across 12 major cancer types, Nature, vol.339, issue.7471, pp.333-342, 2013.
DOI : 10.1126/science.1235122

URL : http://www.nature.com/nature/journal/v502/n7471/pdf/nature12634.pdf

K. König, M. Peifer, J. Fassunke, M. Ihle, H. Künstlinger et al., Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients, Journal of Thoracic Oncology, vol.10, issue.7, pp.1049-57
DOI : 10.1097/JTO.0000000000000570

J. Zugazagoitia, D. Rueda, N. Carrizo, A. Enguita, D. Gómez-sánchez et al., Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non???Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments, Clinical Lung Cancer, 2017.
DOI : 10.1016/j.cllc.2017.06.008

C. Maher, C. Kumar-sinha, X. Cao, S. Kalyana-sundaram, B. Han et al., Transcriptome sequencing to detect gene fusions in cancer, Nature, vol.3, issue.7234, pp.97-101, 2009.
DOI : 10.1101/gr.229202. Article published online before March 2002

Z. Zheng, M. Liebers, B. Zhelyazkova, Y. Cao, D. Panditi et al., Anchored multiplex PCR for targeted next-generation sequencing, Nature Medicine, vol.40, issue.12, pp.1479-84, 2014.
DOI : 10.1093/nar/gks596

E. Moskalev, J. Frohnauer, S. Merkelbach-bruse, H. Schildhaus, A. Dimmler et al., Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing, Lung Cancer, vol.84, issue.3, 2014.
DOI : 10.1016/j.lungcan.2014.03.002

N. Pfarr, A. Stenzinger, R. Penzel, A. Warth, H. Dienemann et al., High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer, Genes, Chromosomes and Cancer, vol.20, issue.1, pp.30-44, 2016.
DOI : 10.1038/nm.3729

T. Rogers, G. Arnau, G. Ryland, S. Huang, M. Lira et al., Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Sci Rep, Feb, vol.97, p.42259, 2017.

M. Takeda, K. Sakai, M. Terashima, H. Kaneda, H. Hayashi et al., Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer, Annals of Oncology, vol.475, 2015.
DOI : 10.1093/annonc/mdv475

M. Pekar-zlotin, F. Hirsch, L. Soussan-gutman, M. Ilouze, A. Dvir et al., Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer. The Oncologist, pp.316-338, 2015.

G. Frampton, A. Fichtenholtz, G. Otto, K. Wang, S. Downing et al., Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing, Nature Biotechnology, vol.11, issue.11, pp.1023-1054, 2013.
DOI : 10.1093/NAR/29.1.308

A. Drilon, L. Wang, M. Arcila, S. Balasubramanian, J. Greenbowe et al., Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches, Clinical Cancer Research, vol.21, issue.16, pp.3631-3640, 2015.
DOI : 10.1158/1078-0432.CCR-14-2683

C. Heydt, A. Kostenko, S. Merkelbach-bruse, J. Wolf, and R. Büttner, ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology, Annals of Oncology, vol.27, issue.suppl_3, pp.25-34, 2016.
DOI : 10.1093/annonc/mdw303

S. Ali, T. Hensing, A. Schrock, A. J. Sanford, E. Gowen et al., -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization, The Oncologist, vol.21, issue.6, 2016.
DOI : 10.1634/theoncologist.2015-0497

URL : https://hal.archives-ouvertes.fr/hal-01483447

J. Gainor, D. Tan, D. Pas, T. Solomon, B. Ahmad et al., Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res, pp.2745-52, 2015.

R. Chiari, G. Metro, D. Iacono, G. Bellezza, A. Rebonato et al., Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis, Lung Cancer, vol.90, issue.2, pp.255-60, 2015.
DOI : 10.1016/j.lungcan.2015.09.009

I. Yeh, A. De-la-fouchardiere, D. Pissaloux, T. Mully, M. Garrido et al., Clinical, Histopathologic, and Genomic Features of Spitz Tumors With ALK Fusions, The American Journal of Surgical Pathology, vol.39, issue.5, pp.581-91
DOI : 10.1097/PAS.0000000000000387

T. Yoshida, Y. Oya, K. Tanaka, J. Shimizu, Y. Horio et al., -Positive Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.34, issue.28, pp.3383-3392, 2016.
DOI : 10.1200/JCO.2015.65.8732

URL : https://hal.archives-ouvertes.fr/hal-01486034

C. Woo, S. Seo, S. Kim, S. Jang, K. Park et al., -rearranged non???small cell lung cancer, Annals of Oncology, vol.693, 2016.
DOI : 10.1093/annonc/mdw693

URL : https://hal.archives-ouvertes.fr/tel-01488898

Y. Lei, J. Yang, X. Zhang, W. Zhong, Q. Zhou et al., Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC, Clinical Lung Cancer, vol.17, issue.3, pp.223-254, 2016.
DOI : 10.1016/j.cllc.2015.09.002

Y. Cha, H. Kim, and H. Shim, Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants Available from, J Transl Med, vol.14, issue.1, 2009.

J. Heuckmann, H. Balke-want, F. Malchers, M. Peifer, M. Sos et al., Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants, Clinical Cancer Research, vol.18, issue.17, pp.4682-90, 2012.
DOI : 10.1158/1078-0432.CCR-11-3260

M. Richards, E. Law, L. Rennalls, S. Busacca, L. O-'regan et al., Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical ??-propeller domain, Proceedings of the National Academy of Sciences, vol.66, issue.Pt 1, pp.5195-200, 2014.
DOI : 10.1107/S0907444909042073

G. Hrustanovic, V. Olivas, E. Pazarentzos, A. Tulpule, S. Asthana et al., RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK???positive lung cancer, Nature Medicine, vol.511, issue.9, pp.1038-1085, 2015.
DOI : 10.1158/1078-0432.CCR-10-0851

A. Hadd, J. Houghton, A. Choudhary, S. Sah, L. Chen et al., Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin-Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens, The Journal of Molecular Diagnostics, vol.15, issue.2, pp.234-281, 2013.
DOI : 10.1016/j.jmoldx.2012.11.006

G. Young, K. Wang, J. He, G. Otto, M. Hawryluk et al., Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms, Cancer Cytopathology, vol.31, issue.suppl 1, pp.688-94, 2013.
DOI : 10.1007/s10637-012-9891-x

H. Karnes, E. Duncavage, and C. Bernadt, Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung, Cancer Cytopathology, vol.12, issue.2, pp.104-117, 2014.
DOI : 10.2353/jmoldx.2010.090238

T. Qiu, H. Guo, H. Zhao, L. Wang, and Z. Zhang, Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology. Sci Rep [Internet] Available from, 2015.

R. Lanman, S. Mortimer, O. Zill, D. Sebisanovic, R. Lopez et al., Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA, PLOS ONE, vol.17, issue.Suppl 5, p.140712, 2015.
DOI : 10.1371/journal.pone.0140712.s006

M. Schwaederle, H. Husain, P. Fanta, D. Piccioni, S. Kesari et al., Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay, Oncotarget, vol.7, issue.9, pp.9707-9724, 2016.
DOI : 10.18632/oncotarget.7110